Skip to Content

Rybelsus (semaglutide) Disease Interactions

There are 5 disease interactions with Rybelsus (semaglutide):

Major

Semaglutide (applies to Rybelsus) thyroid cancer

Major Potential Hazard, Moderate plausibility. Applicable conditions: Thyroid Tumor

The use semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated. Counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors.

Moderate

Semaglutide (applies to Rybelsus) GI adverse events

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Vomiting, Diarrhea, Dehydration, Renal Dysfunction

There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists, such as semaglutide. Some events occurred without underlying renal disease, and the majority of events occurred in patients experiencing gastrointestinal reactions (nausea, vomiting, dehydration). It is recommended to monitor renal function when initiating or escalating doses of semaglutide in patients reporting severe adverse gastrointestinal reactions. No dose adjustment is recommended for patients with renal impairment.

Moderate

Semaglutide (applies to Rybelsus) hypoglycemia

Moderate Potential Hazard, Moderate plausibility.

The concomitant use of semaglutide with insulin and insulin secretagogues (e.g., sulfonylurea) may increase the risk of hypoglycemia. It is recommended to use caution and a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with semaglutide.

Moderate

Semaglutide (applies to Rybelsus) pancreatitis

Moderate Potential Hazard, Moderate plausibility.

Pancreatitis has been reported with the use of semaglutide. It is recommended to carefully observe patients for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting) after therapy initiation. Discontinue treatment if pancreatitis is suspected and manage as appropriate; if confirmed, do not restart treatment with semaglutide and reevaluate for appropriate treatment.

Moderate

Semaglutide (applies to Rybelsus) retinopathy

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetic Retinopathy

Semaglutide should be used with caution in patients with a history of diabetic retinopathy. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. It is recommended to monitor closely for progression of diabetic retinopathy.

Rybelsus (semaglutide) drug interactions

There are 240 drug interactions with Rybelsus (semaglutide)

Rybelsus (semaglutide) alcohol/food interactions

There are 2 alcohol/food interactions with Rybelsus (semaglutide)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.